High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 3, 2000, Pages 675-681

  Yoshioka, Yasuo ^a   Nose, Takayuki ^a   Yoshida, Ken ^a   Inoue, Takehiro ^a   Yamazaki, Hideya ^b   Tanaka, Eiichi ^a   Shiomi, Hiroya ^a   Imai, Atsushi ^a   Nakamura, Satoaki ^a   Shimamoto, Shigetoshi ^a   Inoue, Toshihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Brachytherapy; High dose rate; Hyperfractionated; Monotherapy; Prostate cancer

Indexed keywords

CHLORMADINONE; FLUTAMIDE; GOSERELIN; HORMONE; IRIDIUM 192; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; ECHOGRAPHY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BLADDER NEOPLASMS; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0034306876     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00687-8     Document Type: Article

References (13)

1. Blasko J., Ragde H., Luse R., et al. Should brachytherapy be considered a therapeutic option in localized prostate cancer. Urol Clin NA. 23:1996;633-650.
2. Bayer D.C., Priestley J.B. Biochemical disease-free survival following I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 37:1997;559-563.
3. Stromberg J., Martinez A., Gonzalez J., et al. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer Treatment description and preliminary results of a phase I/II clinical trial . Int J Radiat Oncol Biol Phys. 33:1995;161-171.
4. Kovacs G., Wirth B., Bertermann H., et al. Prostate preservation by combined external beam and HDR brachytherapy at nodal negative prostate cancer patients-an intermediate analysis after ten years experience. (Abstr.) Int J Radiat Oncol Biol Phys. 36:(Suppl. 1):1996;198.
5. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading Ir-192 prostate brachytherapy Feasibility report . Int J Radiat Oncol Biol Phys. 41:1998;525-533.
6. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.
7. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
8. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTG). Int J Radiat Oncol Biol Phys. 31:1995;1341-1346.
9. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 53:1958;457-481.
10. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
11. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment Five year outcomes, treatment optimization, and future directions . Int J Radiat Oncol Biol Phys. 41:1998;501-510.
12. Dawson L.A., Mah K., Franssen E., et al. Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys. 42:1998;1155-1161.
13. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry An analysis based on serial CT acquisition . Int J Radiat Oncol Biol Phys. 41:1998;1069-1077.